Mowoot, member of CataloniaBio & HealthTech, launched a project in collaboration with Eurecat, also members, and the Jordi Gol i Gurina Primary Care Research Foundation to develop a device that becomes the first effective therapy for the treatment of IBS. 

Starting from the basic idea of physically stimulating the intestine - in a non-invasive way - to interact directly with the gastro-intestinal mechanosensory cells and circuits, it could represent a revolutionary new curative treatment for IBS that works in line with the patient's physiology and restores healthy intestinal motility. This new treatment will avoid the side effects and other difficulties of systemic approaches, such as medications. 

The device will be equipped with sensor technology to automatically observe the patient's physiological response to the treatment in real time and will be connected to a digital platform that will collect the results reported by the patient. AI software will collect and analyse the data to adjust the treatment to the patient's physiological state in real time and create reports for healthcare professionals. 

The direct physical stimulation of the cells involved in the digestion process has the potential to correct the dysregulation of colonic motility, secretion, and visceral hypersensitivity. This stimulation acts as a "pacemaker" that restores correct patterns and serotonin secretion, physically interacting with the gut-brain axis and the gut microbiota. 

The project is funded by the Ministry of Science and Innovation within the framework of the 'Next Generation EU' funds and involves the participation of the reference centers EURECAT and IDIAPJGOL. In addition, there is a bridge financing round on the Capital Cell crowdfunding platform to support their entry into the English market where they expect public health reimbursement in 2025.